Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023
May 09, 2023 01:02 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023 Halle (Saale) / Munich, Germany, May 9, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...
Vivoryon Therapeutics N.V. to Report Q1 2023 Financial Results and Operational Progress on May 16, 2023
May 09, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Report Q1 2023 Financial Results and Operational Progress on May 16, 2023 Halle (Saale) / Munich, Germany, May 9, 2023 – Vivoryon Therapeutics N.V. (Euronext...
Vivoryon Therapeutics N.V. Announces Planned Changes to Board Composition at 2023 Annual General Meeting
May 01, 2023 04:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Announces Planned Changes to Board Composition at 2023 Annual General Meeting Halle (Saale) / Munich, Germany, May 1, 2023 – Vivoryon Therapeutics N.V. (Euronext...
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
April 24, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences Halle (Saale) / Munich, Germany, April 24, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a...
Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress
April 19, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress Significantly advanced varoglutamstat EU and U.S. clinical studies, VIVIAD and VIVA-MIND,...
Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023
April 14, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023 Halle (Saale) / Munich, Germany, April 14, 2023 - Vivoryon Therapeutics N.V....
Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease
March 28, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease VIVIAD Phase 2b study in Europe on track for final data readout...
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
February 21, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences Halle (Saale) / Munich, Germany, February 21, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)...
Vivoryon Therapeutics N.V. to Present at the 2023 BIO CEO & Investor Conference
February 03, 2023 08:32 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Present at the 2023 BIO CEO & Investor ConferenceHalle (Saale) / Munich, Germany, February 3, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...